analyse_media
analyse_media
analyse_media
analyse_media
analyse_media
Here is a complete summary and interpretation of all the lab reports for Majidbhai A Agvan, 50-year-old Male, dated 13 July 2026 (from Kansagara Unipath Specialty Laboratory, Keshod), along with the historical tracking sheet from Bhanavadiya Hospital & Diabetes Care.
Complete Lab Report Summary
1. HbA1c (Glycated Hemoglobin) - HPLC Method
| Parameter | Result | Reference |
|---|---|---|
| HbA1c | 8.30% | Normal ≤5.6%, Diabetes ≥6.5% |
| Mean Blood Glucose (estimated) | 192 mg/dL | - |
Interpretation: HbA1c of 8.3% is above the "Good Control" threshold of 7-8%. The lab report itself flags this as "Action Suggested" - meaning the current diabetes management is insufficient and treatment needs to be intensified.
The HPLC chromatogram breakdown confirms no abnormal hemoglobin variants:
- HbA1c fraction: 8.3% | HbF: 1.6% | HbA0 (normal adult Hb): 86.7%
2. Post-Prandial Plasma Glucose (PPBS)
| Parameter | Result | Reference |
|---|---|---|
| PPBS | 180.84 mg/dL | Normal ≤139, Prediabetes 140-199, Diabetes ≥200 |
Interpretation: Falls in the prediabetes/elevated range (140-199). While not at the diabetes cut-off of ≥200, it is significantly above normal and consistent with suboptimal glucose control in a known diabetic.
3. Kidney Function
| Parameter | Result | Reference |
|---|---|---|
| Serum Creatinine | 0.95 mg/dL | 0.70 - 1.20 (Normal) |
| eGFR | 96.83 mL/min/1.73 m² | >90 (Normal - CKD Stage G1) |
Interpretation: Kidney function is currently within normal limits. eGFR >90 is classified as normal/CKD Stage G1. This is reassuring given the long duration of diabetes.
4. Historical Tracking (Bhanavadiya Hospital & Diabetes Care)
| Date | HbA1c | S. Creatinine | RBS/PPBS | Lipids |
|---|---|---|---|---|
| 13/07/2024 | - | - | RBS: 420 mg/dL | - |
| 20/12/2024 | 13.2% | 1.2 | - | - |
| 30/09/2024 | - | - | PPBS: 290 | - |
| 25/02/2025 | - | - | PPBS: 290 | - |
| 29/10/2025 | 7.5% | 0.8 | - | TC: 232.2, TG: 225.9, HDL: 43, LDL: 244.2, Non-HDL: 289.2 |
| 22/06/2025 | - | - | PPBS: 198 | - |
| 22/03/2026 | - | - | RBS: 257 | - |
| 13/07/2026 | 8.3% | 0.9 | PPBS: 280.8 | - |
Trend Analysis:
- HbA1c improved dramatically from a very high 13.2% (Dec 2024) to 7.5% (Oct 2025) - excellent response to treatment
- However, HbA1c has worsened again to 8.3% (July 2026), suggesting glycemic control has slipped
- Blood sugars remain elevated (PPBS 280.8 on tracking sheet vs. 180.84 on the formal lab - these may reflect different days/conditions)
- Creatinine has remained stable (1.2 → 0.8 → 0.9 mg/dL)
5. Lipid Profile (from Oct 2025 - most recent available)
| Parameter | Value | Status |
|---|---|---|
| Total Cholesterol | 232.2 mg/dL | Borderline High (>200) |
| Triglycerides | 225.9 mg/dL | High (>200) |
| HDL | 43 mg/dL | Low (Men: <40 is low, 40-59 borderline) |
| LDL | 244.2 mg/dL | Very High (>190 = very high risk) |
| Non-HDL | 289.2 mg/dL | Very High |
Interpretation: The lipid profile from October 2025 showed significantly abnormal values - particularly LDL at 244.2 mg/dL and Non-HDL at 289.2 mg/dL. For a diabetic patient, the LDL target is typically <70-100 mg/dL (high-risk category). This is a major cardiovascular risk factor that urgently needs attention. A repeat lipid panel should be done now.
Key Concerns & Recommendations
-
Worsening glycemic control - HbA1c has risen from 7.5% to 8.3% over ~9 months. Treatment intensification is needed (medication adjustment, dietary compliance review).
-
Very high LDL (244.2 mg/dL) - In a diabetic patient, this represents very high cardiovascular risk. Statin therapy (if not already on one) or dose optimization is important. A fresh lipid panel should be ordered today.
-
Low HDL (43 mg/dL) and high triglycerides (225.9 mg/dL) - These compound cardiovascular risk and are common in poorly controlled diabetes.
-
Kidney function is currently preserved (eGFR ~97) - this is positive, but UACR (urine albumin-creatinine ratio) is listed on the tracking sheet with no values recorded. This test should be done to screen for early diabetic nephropathy.
-
Missing tests - Several important monitoring tests have never been recorded: UACR, TSH, Vitamin B12, HB (hemoglobin), SGPT, BP, and Uric Acid. B12 is especially important if metformin is being used, as it can cause B12 deficiency.
Important Disclaimer: This analysis is for informational purposes only and does not replace professional medical advice. Please share these results with the treating physician (Dr. Deepa D Vachhani or the diabetes clinic) for proper clinical assessment and any treatment changes.
This is a shared conversation. Sign in to Orris to start your own chat.